Statin use is associated with improved overall survival in patients with melanoma

Research output: Contribution to journalArticlepeer-review

Abstract

Melanoma remains a leading cause of cancer morbidity and mortality. Recent literature suggests that statin use may improve outcomes in patients with cancer. In order to determine whether statins may improve survival in melanoma patients, we analyzed data from the Veterans Health Administration Corporate Data Warehouse that contains individually identifiable clinical and demographic information from the 1990s to the present for over 19 million individual veterans. We found that melanoma patients who were taking a statin had better 5-year OS when compared with veterans not taking statins. This relationship remained significant in a multivariate model (hazard ratio, 0.38; 95% confidence interval, 0.34-0.43 for statin user vs. nonuser). Importantly, this effect was much larger than the effect of statins in the general population and was remained after controlling for the use of other medications (beta-blocker), implying that statins may have a direct effect on survival in melanoma patients.

Original languageEnglish (US)
Pages (from-to)291-294
Number of pages4
JournalMelanoma Research
Volume32
Issue number4
DOIs
StatePublished - Aug 1 2022

Keywords

  • cancer control
  • melanoma
  • metastasis
  • prevention
  • statin
  • survival

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Statin use is associated with improved overall survival in patients with melanoma'. Together they form a unique fingerprint.

Cite this